An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp,Dick de Zeeuw,Merlin C. Thomas,Mark E. Cooper,Pieter A. de Graeff,Hans L. Hillege,Hans-Henrik Parving,Barry M. Brenner,Shahnaz Shahinfar,Hiddo J.L. Heerspink +9 more
Reads0
Chats0
TLDR
The greater the acute fall in glomerular filtration rate, during losartan treatment, the slower the rate of long-term eGFR decline, and interpretation of trial results relying on slope-based GFR outcomes should separate the initial drug-induced GFR change from the subsequent long- term effect on GFR.About:
This article is published in Kidney International.The article was published on 2011-08-01 and is currently open access. It has received 286 citations till now. The article focuses on the topics: Renal function & Angiotensin II.read more
Citations
More filters
Journal ArticleDOI
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Paul K. Whelton,Robert M. Carey,Wilbert S. Aronow,Donald E. Casey,Karen J. Collins,Cheryl Dennison Himmelfarb,Sondra M. DePalma,Samuel S. Gidding,Kenneth Jamerson,Daniel W. Jones,Eric J. MacLaughlin,Paul Muntner,Bruce Ovbiagele,Sidney C. Smith,Crystal C. Spencer,Randall S. Stafford,Sandra J. Taler,Randal J. Thomas,Kim A. Williams,Jeff D. Williamson,Jackson T. Wright +20 more
TL;DR: Since 1980, the American College of Cardiology and American Heart Association have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health.
Journal ArticleDOI
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Paul K. Whelton,Robert M. Carey,Wilbert S. Aronow,Donald E. Casey,Karen J. Collins,Cheryl Dennison Himmelfarb,Sondra M. DePalma,Samuel S. Gidding,Kenneth Jamerson,Daniel W. Jones,Eric J. MacLaughlin,Paul Muntner,Bruce Ovbiagele,Sidney C. Smith,Crystal C. Spencer,Randall S. Stafford,Sandra J. Taler,Randal J. Thomas,Kim A. Williams,Jeff D. Williamson,Jackson T. Wright +20 more
TL;DR: The next generation of scientists and decision-makers will have a greater understanding of what constitutes a credible threat to public health and how to protect them from that threat.
Journal ArticleDOI
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
TL;DR: In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.
Journal ArticleDOI
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
TL;DR: Some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.
Journal ArticleDOI
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Katherine R. Tuttle,George L. Bakris,Rudolf W. Bilous,Jane L. Chiang,Ian H. de Boer,Jordi Goldstein-Fuchs,Irl B. Hirsch,Kamyar Kalantar-Zadeh,Andrew S. Narva,Sankar D. Navaneethan,Joshua J. Neumiller,Uptal D. Patel,Robert E. Ratner,Adam Whaley-Connell,Mark E. Molitch +14 more
TL;DR: This current state summary and research recommendations are designed to guide advances in care and the generation of new knowledge that will meaningfully improve life for people with DKD.
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Edmond J Lewis,Lawrence G. Hunsicker,William R. Clarke,Tomas Berl,Marc A. Pohl,Julia B. Lewis,Eberhard Ritz,Robert C. Atkins,Richard D. Rohde,Itamar Raz +9 more
TL;DR: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Journal ArticleDOI
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Hans-Henrik Parving,Hendrik Lehnert,Jens Bröchner-Mortensen,Ramon Gomis,Steen Andersen,Peter Arner +5 more
TL;DR: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug.
Journal Article
Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Hans-Henrik Parving,Hendrik Lehnert,Jens Bröchner-Mortensen,Ramon Gomis,Steen Andersen,Peter Arner +5 more
TL;DR: In this article, the authors evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria.